RADX Latest Press Releases

-- November 9, 2026 --

UPDATE - International companies to host live webcasts at Deutsche Bank's Depositary Receipts Virtual Investor Conference on November 12, 2026 Globe Newswire 11:56 AM

-- November 5, 2026 --

International companies to host live webcasts at Deutsche Bank's Depositary Receipts Virtual Investor Conference on November 12, 2026 Globe Newswire 8:35 AM

-- November 4, 2026 --

Radiopharm Theranostics Announces Alignment with U.S. FDA on Single Pivotal Phase 3 Trial for RAD101 in Diagnosis of Brain Metastases Globe Newswire 7:00 AM

-- November 2, 2026 --

Radiopharm Theranostics Reports Business Update Globe Newswire 8:00 AM

-- October 5, 2026 --

Radiopharm Completes Productive End-of-Phase 2 Meeting with U.S. Food and Drug Administration for Pivotal Development Program of RAD101 Globe Newswire 8:00 AM

-- September 14, 2026 --

Radiopharm Theranostics Selected for Late-Breaking Oral Presentation of Positive Data from Interim Analysis of U.S. Phase 2b Imaging Trial of RAD101 at 2026 Society of Neuro-Oncology Annual Meeting Globe Newswire 8:00 AM

-- September 9, 2026 --

Radiopharm Theranostics Announces Positive Data from the Phase 1 Imaging Trial of RAD301 in Patients with Pancreatic Ductal Adenocarcinoma Globe Newswire 7:00 AM

-- August 26, 2026 --

Radiopharm Theranostics Doses First Patient in Second Cohort of Phase 1/2a Clinical Trial of BetaBart (RV-01) in B7-H3 Expressing Solid Tumors Globe Newswire 7:00 AM

-- August 20, 2026 --

Radiopharm Theranostics Receives Positive Recommendation from Data Safety and Monitoring Committee to Advance to Cohort 4 in 177Lu-RAD202 Phase 1 HEAT Clinical Trial Globe Newswire 7:00 AM

-- August 17, 2026 --

Radiopharm Theranostics To Meet with U.S. FDA to Align on Pivotal Phase 3 Trial Design for RAD 101 in Diagnosis of Brain Metastases Globe Newswire 7:30 AM

-- July 31, 2026 --

Radiopharm Theranostics Reports Business Update Globe Newswire 7:00 AM

-- July 24, 2026 --

Radiopharm Theranostics Announces Concurrent US$4.1 Million Registered Direct Offering and Up To Additional A$12.7 (US$8.9) Million Australian Placement and Share Purchase Plan Globe Newswire 7:15 AM

-- July 22, 2026 --

Radiopharm Theranostics Achieves Confirmed Durable Partial Response in Ongoing Phase 1 Trial of RAD204 in Patients with Advanced Solid Tumors Post-Immunotherapy Globe Newswire 7:05 AM

Radiopharm Theranostics Announces Positive Phase 2b Trial Results of RAD 101 for Diagnosis of Brain Metastases Globe Newswire 7:00 AM

Market Data Delayed 15 Minutes